Difference between revisions of "Methotrexate"

From Dog
Line 6: Line 6:
 
This drug is rarely used alone and is used in treatment of [[lymphoma]] in combination with [[L-asparaginase]], [[vincristine]], [[cyclophosphamide]], [[doxorubicin]] and [[prednisolone]]<ref>Simon D ''et al'' (2008) Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. ''J Am Vet Med Assoc'' '''232(6)''':879-885</ref>.
 
This drug is rarely used alone and is used in treatment of [[lymphoma]] in combination with [[L-asparaginase]], [[vincristine]], [[cyclophosphamide]], [[doxorubicin]] and [[prednisolone]]<ref>Simon D ''et al'' (2008) Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. ''J Am Vet Med Assoc'' '''232(6)''':879-885</ref>.
  
The main side-effects of this drug are vomiting, diarrhea and bone marrow suppression<ref>Yu C ''et al'' (2000) Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model. ''Transplantation'' '''69(3)''':450-454</ref>, and in some dogs, a [[protein-losing enteropathy]] may ensue, requiring special attention<ref>Yuki M ''et al'' (2006) A case of protein-losing enteropathy treated with methotrexate in a dog. ''J Vet Med Sci'' '''68(4)''':397-399</ref>.
+
The main side-effects of this drug are vomiting, diarrhea and bone marrow suppression<ref>Yu C ''et al'' (2000) Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model. ''Transplantation'' '''69(3)''':450-454</ref> characterized by [[leucopenia]], and in some dogs, a [[protein-losing enteropathy]] may ensue, requiring special attention<ref>Yuki M ''et al'' (2006) A case of protein-losing enteropathy treated with methotrexate in a dog. ''J Vet Med Sci'' '''68(4)''':397-399</ref>.
  
 
High-doses of [[folic acid]] are usually administered to accelerate methotrexate elimination to avoid [[acute renal injury]]<ref>Takeuchi A ''et al'' (2001) Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. ''Kidney Int'' '''60(3)''':1058-1068</ref>.
 
High-doses of [[folic acid]] are usually administered to accelerate methotrexate elimination to avoid [[acute renal injury]]<ref>Takeuchi A ''et al'' (2001) Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. ''Kidney Int'' '''60(3)''':1058-1068</ref>.

Revision as of 01:15, 7 March 2013

Methotrexate is an antimetabolite chemotherapy drug.

This drug competitively inhibits dihydrofolic acid reductase, which is normally reduced to tetrahydrofolates in purine nucleotide and thymidine synthesis. Thus, methotrexate interferes with DNA synthesis, repair, and cellular replication.

This drug is rarely used alone and is used in treatment of lymphoma in combination with L-asparaginase, vincristine, cyclophosphamide, doxorubicin and prednisolone[1].

The main side-effects of this drug are vomiting, diarrhea and bone marrow suppression[2] characterized by leucopenia, and in some dogs, a protein-losing enteropathy may ensue, requiring special attention[3].

High-doses of folic acid are usually administered to accelerate methotrexate elimination to avoid acute renal injury[4].

Recommended dose is 2.5 mg/m2 orally once daily or 5.0 mg/m2 orally on days 1 and 5 of a biweekly maintenance schedule.

References

  1. Simon D et al (2008) Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. J Am Vet Med Assoc 232(6):879-885
  2. Yu C et al (2000) Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model. Transplantation 69(3):450-454
  3. Yuki M et al (2006) A case of protein-losing enteropathy treated with methotrexate in a dog. J Vet Med Sci 68(4):397-399
  4. Takeuchi A et al (2001) Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. Kidney Int 60(3):1058-1068